Nano-X Imaging (NASDAQ:NNOX – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare Nano-X Imaging to related businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Nano-X Imaging and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nano-X Imaging | 1 | 2 | 2 | 0 | 2.20 |
| Nano-X Imaging Competitors | 4330 | 10559 | 18358 | 840 | 2.46 |
Nano-X Imaging currently has a consensus price target of $4.33, suggesting a potential upside of 1,784.06%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.77%. Given Nano-X Imaging’s higher possible upside, research analysts plainly believe Nano-X Imaging is more favorable than its competitors.
Profitability
This table compares Nano-X Imaging and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nano-X Imaging | -926.05% | -116.93% | -100.67% |
| Nano-X Imaging Competitors | -191.42% | -197.86% | -21.83% |
Earnings & Valuation
This table compares Nano-X Imaging and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nano-X Imaging | $15.63 million | -$75.02 million | -0.11 |
| Nano-X Imaging Competitors | $1.90 billion | $136.32 million | 5.94 |
Nano-X Imaging’s competitors have higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Nano-X Imaging has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Nano-X Imaging’s competitors have a beta of 2.57, meaning that their average share price is 157% more volatile than the S&P 500.
Insider and Institutional Ownership
21.5% of Nano-X Imaging shares are owned by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 7.7% of Nano-X Imaging shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Nano-X Imaging competitors beat Nano-X Imaging on 11 of the 13 factors compared.
Nano-X Imaging Company Profile
Nano-X Imaging Ltd. is an Israeli medical technology company developing digital X-ray imaging systems and related services. Its Nanox.ARC system is designed to produce medical images using the company’s digital X-ray technology, with the goal of expanding access to diagnostic imaging. The company’s broader offering includes Nanox.CLOUD, a cloud-based platform intended to connect imaging systems with image-management and diagnostic services, and Nanox.AI, which develops artificial-intelligence tools for analyzing medical images.
Receive News & Ratings for Nano-X Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nano-X Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
